Skip to main content

Organogenesis Holdings Inc.

corporate_fare Company Profile

Organogenesis Holdings Inc.

ORGO·NASDAQ·Life Sciences·CIK 0001661181

Organogenesis is a regenerative medicine company that develops, manufactures, and sells products for the advanced wound care and surgical and sports medicine markets. The company's products aim to advance healing and recovery. Several products have Premarket Application ("PMA") approval or 510(k) clearance from the United States Food and Drug Administration ("FDA"). Organogenesis serves hospitals, wound care centers, government facilities, ambulatory surgery centers ("ASCs"), and physician offices. In the Advanced Wound Care market, Organogenesis develops and commercializes products for chronic and acute wounds. This portfolio includes Apligraf for venous leg ulcers ("VLUs") and diabetic foot ulcers ("DFUs"); Dermagraft for DFUs (manufacturing and distribution are currently suspended pending transition to a new manufacturing facility in Smithfield, RI); PuraPly AM and PuraPly XT as an antimicrobial barrier and native, cross-linked extracellular matrix scaffold; CYGNUS Dual as a dual-layered amniotic membrane; CYGNUS Matrix as a dehydrated placental allograft; VIA Matrix, Affinity, Novachor, and NuShield placental allografts; and SimpliMax as a dehydrated amnion allograft. In the Surgical & Sports Medicine market, the company addresses chronic and acute surgical wounds and tendon and ligament injuries.

Organogenesis Holdings Inc. (NASDAQ:ORGO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 10 items for ORGO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 8/10. Across its 10 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for ORGO spans 10-Q, 8-K, 424B5, 10-K.

Recent high-impact activity:

  • Organogenesis 10-Q: Revenue Down 70%, Cash Falls to $21.3M, Amnuvx BLA Timeline Slips
  • Revenue Collapses 70% as Organogenesis Swings to $29.6M Quarterly Loss, Cuts Full-Year Outlook
  • Organogenesis Taps $75M At-the-Market Equity Program to Shore Up Liquidity
  • Organogenesis Launches $75M ATM Equity Program After Q2 Revenue Plunge and Guidance Cut
  • Organogenesis Q2 Revenue Plunges 58%, Loss Widens to $96M; Guidance Slashed

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$564.17M
Net Income
$37.03M
Diluted EPS
$0.15
Op. Cash Flow
-$10.31M
Free Cash Flow
-$24.46M
Operating Income
$44.69M
Cash & Equivalents
$93.68M
Debt / Equity
0.00×
Net Margin
6.6%
Shares Outstanding
126.95M sh
Source: 10-K · filed 2026-02-26 · accession 0001193125-26-076730

Short Interest & Short Volume

14.03 days to cover

FINRA reported short interest of 15,614,671 shares in ORGO as of the October 30, 2026 settlement, a 0.2% increase from the prior period — about 14.0 days to cover at its recent average daily volume. On November 20, 2026, 83.6% of ORGO volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)15,614,671 shares as of October 30, 2026
Change vs prior period▲ 0.2%
Days to cover14.03 at avg daily volume of 1,113,277
Daily short volume (FINRA facilities)83.6% of 376,504 shares on November 20, 2026
5-day average short volume69.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

High risk

Filing-implied dilution signals for ORGO, detected from its recent SEC filings · based on capital-structure filings through 2026-08-06.

1 recent capital raiseATM program

$75M ATM Program Established · Highly Dilutive at Current Prices

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with O →
$0.7716
52-week range · as of 2026-11-05 $0.73 – $7.08
Market cap
$100.16M
Volume
792.6K (0.8× avg)
3-mo avg 1.1M
Live data · 2026-11-22 05:12 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ORGO - Latest Insights

ORGO
Nov 05, 2026, 4:17 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.7875
Real-time Price: $0.7716 info
Change: -$0.0159 (-2%) info
Market Cap: $100.155M info
ORGO
Nov 05, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.7624
Real-time Price: $0.7716 info
Change: +$0.0092 (+1%) info
Market Cap: $100.155M info
ORGO
Aug 06, 2026, 4:45 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.97
Real-time Price: $0.7716 info
Change: -$1.20 (-61%) info
Market Cap: $100.155M info
ORGO
Aug 06, 2026, 4:42 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $1.97
Real-time Price: $0.7716 info
Change: -$1.20 (-61%) info
Market Cap: $100.155M info
ORGO
Aug 06, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.32
Real-time Price: $0.7716 info
Change: -$1.55 (-67%) info
Market Cap: $100.155M info
ORGO
Jul 06, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.50
Real-time Price: $0.7716 info
Change: -$1.73 (-69%) info
Market Cap: $100.155M info
ORGO
May 07, 2026, 4:16 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.35
Real-time Price: $0.7716 info
Change: -$1.58 (-67%) info
Market Cap: $100.155M info
ORGO
Apr 06, 2026, 7:02 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.56
Real-time Price: $0.7716 info
Change: -$1.79 (-70%) info
Market Cap: $100.155M info
ORGO
Feb 26, 2026, 4:15 PM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $3.82
Real-time Price: $0.7716 info
Change: -$3.05 (-80%) info
Market Cap: $100.155M info
ORGO
Feb 26, 2026, 4:09 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.85
Real-time Price: $0.7716 info
Change: -$3.08 (-80%) info
Market Cap: $100.155M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets